Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Study of the Fimasartan effects on cardiovascular events and metabolic syndrome in patients with hypertension

X
Trial Profile

Study of the Fimasartan effects on cardiovascular events and metabolic syndrome in patients with hypertension

Status: Completed
Phase of Trial: Phase IV

Latest Information Update: 15 Mar 2019

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Fimasartan (Primary)
  • Indications Essential hypertension
  • Focus Adverse reactions
  • Acronyms K-MetS
  • Sponsors Boryung
  • Most Recent Events

    • 10 Nov 2016 Status changed from recruiting to completed, according to the Korean Clinical Trials Register record.
    • 29 Sep 2016 Results (n=777) assessing short-term changes of metabolic syndrome and blood pressure in hypertensive women, presented at the 26th Scientific Meeting of the International Society of Hypertension
    • 29 Sep 2016 Efficacy and safety 1-year follow-up results (n=2363) of elderly patients were presented at the 26th Scientific Meeting of the International Society of Hypertension.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top